Greg joined Rubius Therapeutics in March of 2019 to lead Quality as the company enters clinical trials for the first-ever investigation of genetically engineered red blood cells for the potential treatment of phenylketonuria, a rare metabolic disorder, and advances additional Investigational New Drug applications in rare diseases, cancer and autoimmune diseases. Prior to joining Rubius, he served as vice president, quality at bluebird bio. In the four years at bluebird bio, Greg oversaw a 10-fold expansion of the Quality Unit to support multiple gene therapy clinical trials and prepare for commercial production in the U.S. and Europe. With strong leadership, Greg established a culture of quality dedicated to patient safety and data integrity. Prior to bluebird, Greg spent 10 years at Dendreon, most recently serving as director, corporate Quality. While there, he established the corporate quality vision and mission and the company’s strategic roadmap for continuous improvement in quality systems. He also led critical initiatives, including regulatory interactions and the successful transition from clinical to commercial production upon product approval. Earlier, Greg was a supervisor of bioanalytic chemistry at BioPort Corporation in Michigan and lead medical technologist in the toxicology testing center at Sparrow Health System in Michigan. Greg received his B.S. in forensic science from Michigan State University.